Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
about
Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic DiseasesA Computational Approach to Identify a Potential Alternative Drug With Its Positive Impact Toward PMP22.Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome.Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome.A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis.Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis
P2860
Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Decitabine for Treatment of My ...... An Open-Label, Phase-3b Study
@ast
Decitabine for Treatment of My ...... An Open-Label, Phase-3b Study
@en
type
label
Decitabine for Treatment of My ...... An Open-Label, Phase-3b Study
@ast
Decitabine for Treatment of My ...... An Open-Label, Phase-3b Study
@en
prefLabel
Decitabine for Treatment of My ...... An Open-Label, Phase-3b Study
@ast
Decitabine for Treatment of My ...... An Open-Label, Phase-3b Study
@en
P2093
P2860
P1433
P1476
Decitabine for Treatment of My ...... An Open-Label, Phase-3b Study
@en
P2093
Baoan Chen
Changgeng Ruan
Guangsheng He
Hongchuang Liang
Jianyong Li
P2860
P2888
P304
P356
10.1007/S12325-015-0263-8
P407
P577
2015-11-14T00:00:00Z